
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure is currently experiencing strong demand and growth in all markets due to a record revenue quarter, demonstrating strong execution on the commercial side. The recent CEMark for Optune Pax in locally advanced pancreatic cancer and the addition of TTFields as an NCCN Category 2A recommendation for brain metastases from NSCLC also support the company's anticipated growth. Additionally, NovoCure is engaging in strategic partnerships and exploring potential indications for TTFields, adding to the company's potential future success.
Bears say
NovoCure is seeing strong revenue growth but this is largely attributed to one-time revenue benefits and early launch metrics for Optune Pax, which may not be sustainable in the long-term. Despite an encouraging launch in Japan for Optune Lua, competition in the lung cancer market and limited treatment duration may pose challenges for sustained growth. Furthermore, with the failure of TRIDENT, concerns about durable adoption and franchise expansion remain. Lowering their price target to $46 due to potential long-term growth limitations.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares